Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Cordis Asset Management is a boutique investment management firm based in Sydney, Australia, founded in 2020. The firm specializes in publicly listed medical technology companies, focusing on high-growth opportunities within the medtech sector. Cordis leverages global megatrends, particularly the aging population and advancements in medical technology, to generate investment returns for its clients.
As of now, Cordis Asset Management operates the Cordis Global Medical Technology Fund, which is designed to provide investors with exposure to high-growth medical technology investments. The firm is benchmark-agnostic, allowing for flexibility in investment decisions across various geographies and market capitalizations. Cordis Asset Management has established itself as a thought leader in the medtech investment space, actively publishing insights and reports that inform investment strategies and market trends.
Cordis Asset Management exclusively invests in the medical technology sector, categorizing its investments into three main buckets: earnings compounders, high growth companies, and emerging opportunities. The firm’s investment strategy is based on two primary themes: the aging global population, which represents the fastest-growing demographic with the highest health expenditure, and the medical technology revolution, which enables more effective patient treatment.
The firm adopts a benchmark-agnostic approach, allowing it to invest flexibly across various geographies and market capitalizations. Cordis seeks to capitalize on secular shifts in the market, focusing on companies that demonstrate strong growth potential and innovative solutions in healthcare. The check size range for investments typically starts at AUD $50,000, making it accessible for various investment opportunities.
Cordis Asset Management has built a notable portfolio of leading medical technology companies recognized for their innovative medical devices and significant contributions to chronic disease treatment. The portfolio includes:
These companies are at the forefront of medical technology, contributing to advancements in healthcare and improving patient outcomes.
Michael Cartmill: Co-founder & CEO, brings extensive experience in investment management and healthcare.
Jacob Celermajer: Portfolio Manager, specializes in equity analysis and portfolio management within the medical technology sector.
Professor Michael Vallely: Chair of the Medical Advisory Panel, a renowned cardiovascular surgeon with significant expertise in medical technology.
Andy Laing: Head of Distribution, responsible for managing investor relations and distribution strategies.
Oliver Welch: Member of the Distribution Team, supports the firm's outreach and investor engagement efforts.
David Celermajer: Member of the Medical Advisory Panel, contributing insights from a medical perspective to the investment strategy.
To pitch to Cordis Asset Management, founders should send an email to enquiries@cordisam.com. It is important to include a comprehensive deck that outlines the business model, market opportunity, competitive landscape, and financial projections. The firm prefers detailed information that showcases how the startup aligns with their investment focus on medical technology.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions through mutual connections in the medical technology sector can enhance the chances of a favorable response.
Cordis Asset Management operates the Cordis Global Medical Technology Fund, designed to provide investors with exposure to high-growth medical technology investments. This fund is actively managed and focuses on a concentrated portfolio of global listed medtech stocks.
Details regarding cohort sizes, investment amounts, or application deadlines for the fund were not provided, but interested investors can reach out directly for more information.
In June 2021, Cordis Asset Management launched the Cordis Global Medical Technology Fund, which focuses on high-growth medical technology investments. The fund is actively managed and aims to provide investors with exposure to 20-40 global listed medtech stocks.
Recently, Cordis Asset Management has been publishing insights through the 'AFR Cordis Monday Fundie,' which discusses investment strategies and market insights. The firm also hosts webinars to provide updates on investment performance and market trends, indicating ongoing engagement with their audience.
What are Cordis Asset Management's investment criteria?
Cordis Asset Management focuses exclusively on the medical technology sector, investing in publicly listed companies that demonstrate strong growth potential. The firm categorizes its investments into earnings compounders, high growth companies, and emerging opportunities, allowing for a diversified approach within the medtech space.
How can I pitch my startup to Cordis Asset Management?
Founders can reach out via email at enquiries@cordisam.com to initiate a pitch. It is advisable to include a detailed business plan, market analysis, and information on the team and technology. A clear articulation of how the startup aligns with Cordis's investment focus on medical technology will enhance the chances of a favorable response.
What makes Cordis Asset Management different from other investors?
Cordis Asset Management distinguishes itself through its exclusive focus on the medical technology sector and its benchmark-agnostic investment strategy. The firm leverages deep industry expertise and a network of medical professionals to provide valuable insights and support to its portfolio companies.
What is the geographic scope of Cordis Asset Management's investments?
The firm is geographically agnostic, allowing it to invest in medical technology companies across the globe. This flexibility enables Cordis to capitalize on high-growth opportunities regardless of location.
What is the typical check size for investments?
Cordis Asset Management typically starts its investments at AUD $50,000, making it accessible for various investment opportunities within the medical technology sector.
What kind of post-investment involvement does Cordis Asset Management have?
Cordis Asset Management actively engages with its portfolio companies through its deep industry expertise and access to a network of medical professionals. The firm also publishes insights and reports that inform investment strategies and market trends, enhancing the overall investment experience for its clients.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.